Management of Intertrigo with Topical Corticosteroids

Introduction to Intertrigo Treatment

The American Academy of Dermatology warns that face and intertriginous areas are at greatest risk to develop adverse effects from topical corticosteroids, including skin atrophy, striae, folliculitis, telangiectasia, and purpura 2
Triamcinolone acetonide 0.5% is classified as a high-potency (Class 3) topical corticosteroid, which is not suitable for intertrigo treatment due to high risk of skin atrophy and other adverse effects in sensitive skin folds 1

If inflammation requires corticosteroid treatment, lower-potency formulations should be used for limited periods, such as Class I-II topical steroids, which may be used for limited time periods 3
The American Academy of Dermatology recommends using lower-potency formulations, such as triamcinolone 0.1% cream (Class 4, upper mid-potency), if a corticosteroid is deemed necessary, and use should be time-limited with close monitoring 1, 3

The American Academy of Dermatology recommends topical calcineurin inhibitors (tacrolimus 0.1% ointment or pimecrolimus 1% cream) as steroid-sparing agents, particularly useful for intertriginous areas, to avoid the atrophy risk associated with corticosteroids 1, 2

Using a potent corticosteroid like triamcinolone 0.5% may exacerbate tinea infections 2
The increased occlusion and moisture in skin folds dramatically increases corticosteroid absorption and adverse effect risk, leading to irreversible striae and significant skin atrophy that persists long after discontinuation 1, 2